Dec 10, 2024 9:00am EST Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
Dec 03, 2024 9:00am EST Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Nov 13, 2024 4:15pm EST Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Oct 08, 2024 4:15pm EDT Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
Sep 17, 2024 5:15pm EDT Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Sep 16, 2024 9:00pm EDT Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Sep 05, 2024 4:05pm EDT Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
Aug 07, 2024 4:05pm EDT Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Jul 17, 2024 9:00am EDT Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
